ATE441665T1 - Scavenger-rezeptoren - Google Patents

Scavenger-rezeptoren

Info

Publication number
ATE441665T1
ATE441665T1 AT01902805T AT01902805T ATE441665T1 AT E441665 T1 ATE441665 T1 AT E441665T1 AT 01902805 T AT01902805 T AT 01902805T AT 01902805 T AT01902805 T AT 01902805T AT E441665 T1 ATE441665 T1 AT E441665T1
Authority
AT
Austria
Prior art keywords
same
proteins
scavenger receptors
lipoproteinemia
elucidation
Prior art date
Application number
AT01902805T
Other languages
English (en)
Inventor
Nobutaka Wakamiya
Original Assignee
Fuso Pharmaceutical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Ind filed Critical Fuso Pharmaceutical Ind
Application granted granted Critical
Publication of ATE441665T1 publication Critical patent/ATE441665T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
AT01902805T 2000-02-14 2001-02-08 Scavenger-rezeptoren ATE441665T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000035155 2000-02-14
JP2000309068 2000-10-10
PCT/JP2001/000874 WO2001059107A1 (en) 2000-02-14 2001-02-08 Novel scavenger receptors

Publications (1)

Publication Number Publication Date
ATE441665T1 true ATE441665T1 (de) 2009-09-15

Family

ID=26585296

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01902805T ATE441665T1 (de) 2000-02-14 2001-02-08 Scavenger-rezeptoren

Country Status (12)

Country Link
US (5) US7189809B2 (de)
EP (1) EP1262546B1 (de)
JP (1) JP4685315B2 (de)
KR (1) KR100514521B1 (de)
CN (1) CN100485035C (de)
AT (1) ATE441665T1 (de)
AU (2) AU2001230594B2 (de)
CA (1) CA2399865C (de)
DE (1) DE60139765D1 (de)
DK (1) DK1262546T3 (de)
ES (1) ES2331107T3 (de)
WO (1) WO2001059107A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059107A1 (en) * 2000-02-14 2001-08-16 Fuso Pharmaceutical Industries, Ltd. Novel scavenger receptors
WO2006093932A2 (en) * 2005-03-01 2006-09-08 Cedars-Sinai Medical Center Use of eotaxin as a diagnostic indicator for atherosclerosis and vascular inflammation
WO2007139120A1 (ja) * 2006-05-30 2007-12-06 Osaka University アミロイドβクリアランス促進剤
JPWO2011108281A1 (ja) * 2010-03-04 2013-06-20 扶桑薬品工業株式会社 虚血性疾患亢進作用を有するポリペプチド
CN110226567A (zh) * 2019-06-19 2019-09-13 北京林业大学 一种利用黑腹果蝇评价邻苯二甲酸酯类增塑剂的生殖毒性的方法
CN113430985A (zh) * 2021-07-02 2021-09-24 广西壮族自治区自然资源生态修复中心 乡村河道多层式生态保护修复方法
WO2024195854A1 (ja) * 2023-03-23 2024-09-26 積水メディカル株式会社 肺サーファクタントプロテインｄの測定方法、測定キット、モノクローナル抗体及び細胞

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK570485D0 (da) * 1985-12-10 1985-12-10 Novo Industri As Humant conglutinin
FI900808A7 (fi) 1987-08-20 1990-02-19 Childrens Medical Center Ihmisen mannoosia sitova proteiini
US5270199A (en) * 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
JPH079124B2 (ja) 1988-07-28 1995-02-01 株式会社城南製作所 駆動装置
JP2504581B2 (ja) 1989-09-08 1996-06-05 富士通株式会社 ディジタル信号伝送方式
US5866373A (en) * 1995-04-21 1999-02-02 Human Genome Sciences, Inc. Polynucleotide encoding a human chemotactic protein
EP0856580A4 (de) 1995-08-17 2001-02-07 Fuso Pharmaceutical Ind Rekombinantes conglutinin und verfahren zu dessen herstellung
JPH09238683A (ja) 1996-03-12 1997-09-16 Eijiin Kenkyusho:Kk ウェルナー症候群の原因遺伝子の存在する領域にある新規ｗｓ−３遺伝子及びその遺伝子がコードするタンパク質
JP3233057B2 (ja) 1997-02-27 2001-11-26 日本鋼管株式会社 溶融めっき鋼板のスパングルサイズの測定方法
WO1998055614A2 (en) * 1997-06-04 1998-12-10 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP3878737B2 (ja) 1998-01-23 2007-02-07 扶桑薬品工業株式会社 新規コレクチン
ES2279629T3 (es) * 1998-08-24 2007-08-16 Fuso Pharmaceutical Industries Ltd. Nueva colectina.
CA2372815A1 (en) * 1999-05-11 2000-11-16 Incyte Genomics, Inc. Extracellular matrix and adhesion-associated proteins
WO2001059107A1 (en) * 2000-02-14 2001-08-16 Fuso Pharmaceutical Industries, Ltd. Novel scavenger receptors
AU4884001A (en) 2000-04-21 2001-11-07 Fuso Pharmaceutical Ind Novel collectins

Also Published As

Publication number Publication date
US7612174B2 (en) 2009-11-03
US20070224649A1 (en) 2007-09-27
WO2001059107A1 (en) 2001-08-16
CN1646689A (zh) 2005-07-27
CN100485035C (zh) 2009-05-06
DE60139765D1 (de) 2009-10-15
KR100514521B1 (ko) 2005-09-14
US8410253B2 (en) 2013-04-02
EP1262546A1 (de) 2002-12-04
ES2331107T3 (es) 2009-12-22
DK1262546T3 (da) 2010-01-04
US20100113750A1 (en) 2010-05-06
US20030108904A1 (en) 2003-06-12
AU2001230594B2 (en) 2004-11-11
CA2399865A1 (en) 2001-08-16
US20070231859A1 (en) 2007-10-04
US20100113749A1 (en) 2010-05-06
EP1262546B1 (de) 2009-09-02
KR20020089351A (ko) 2002-11-29
EP1262546A4 (de) 2004-07-14
US8084578B2 (en) 2011-12-27
AU3059401A (en) 2001-08-20
JP4685315B2 (ja) 2011-05-18
US7612175B2 (en) 2009-11-03
CA2399865C (en) 2011-10-25
US7189809B2 (en) 2007-03-13

Similar Documents

Publication Publication Date Title
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
CY1118606T1 (el) Πολυπεπτιδικα εμβολια για ευρεια παραγωγη εναντι υπερμολυσματικων μηνιγγιοκοκκιkων σειρων
AU2003270643A1 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
EP1731166A3 (de) Streptococcus pneumoniae Proteine und Impfstoffe
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
AU2002223640A1 (en) Fusion proteins as immunization treatments of alzheimer's disease
PT1200105E (pt) Factor viii modificado
CY1116776T1 (el) Αντισωματα ειδικα για τα διαλυτα πρωτοϊνιδια των πεπτιδιων β-αμυλοειδους και χρησεις αυτων
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
AT500379B1 (de) Tau-proteine
BR0213941A (pt) Arranjos de antìgeno para o tratamento de doença óssea
ATE441665T1 (de) Scavenger-rezeptoren
Laustsen et al. In vivo neutralization of myotoxin II, a phospholipase A2 homologue from Bothrops asper venom, using peptides discovered via phage display technology
EP1270588A4 (de) NEUESKOLLAGEN-äHNLICHES PROTEIN CLAC, DESSEN VORLäUFER UND DAFüR KODIERENDE GENE
WO2002057796A3 (en) Compounds for treating pathologies associated with molecular crystallization
EP1299724A2 (de) Synthetische peptide gegen neurologische krankheiten
DE60226253D1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
Sato et al. Roles of basic amino acid residues in the activity of μ‐conotoxin GIIIA and GIIIB, peptide blockers of muscle sodium channels
ATE401402T1 (de) Mit syndekan interagierende proteine und deren verwendung
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same
AU2002314193A1 (en) Identification of ses-1 and the uses of the same
Vale et al. Exploring the Solid‐Phase Synthesis of Sulfotyrosine Peptides
ATE374784T1 (de) Lösliche komplexe von zielproteinen und peptidyl- prolyl-isomerase-chaperonen sowie deren herstellung und verwendung
WO2002085924A3 (en) ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties